Back to News

GVK Biosciences Licenses its Biomarker Database to The Division of Cancer Prevention, National Cancer Institute

Hyderabad, India — September 04, 2012 — GVK Biosciences (GVK BIO), Asia’s leading contract research organization announced today that it has licensed its popular clinical biomarker database (GOBIOM) to the prestigious Division of Cancer Prevention (DCP), National Cancer Institute (NCI).

The GOBIOM (GVK BIO Online Biomarker Database) is a comprehensive collection of all clinically evaluated, exploratory and preclinical biomarkers associated with different therapeutic areas reported in global clinical trials, clinical and preclinical studies. GOBIOM contains information on 15,500 biomarkers comprising of Biochemical, Genomic, Imaging, Metabolite, Cellular and Physiological markers with multiple data points covering experimental, analytical, clinical, preclinical and statistical data with their qualifications under different medical interventions. GOBIOM covers over 100 different ethnicities, provides extensive information on approved assay methodologies & companion diagnostics and is a powerful tool for researchers and clinicians worldwide. Biomarker Research is growing exponentially in the area of Oncology. The GVK Database has over 6000 Clinically evaluated markers in oncology and growing.

“GVK BIO is pleased that the DCP chose the GVK BIO Biomarker Database for its research efforts. It is a clear testimony to the quality, content and utility of the database. We look forward to working with DCP. The coverage in Oncology will enable researchers at the DCP to accelerate their discovery efforts”, said Sreeni Devidas, Vice President, Sales & Marketing – Informatics.

About GVK Biosciences
GVK Biosciences (GVK BIO) is Asia’s leading contract research organization. GVK BIO provides a broad spectrum of services, stand-alone and integrated, across the R&D value chain. Our discovery services consist of Chemistry, Biology and Informatics; the development services include Clinical Research, Clinical Pharmacology and Process R&D. GVK BIO’s diverse portfolio of nearly 200 customers includes some of the world’s largest pharmaceutical, biotechnology, agro, life-sciences companies and leading academic & research institutions.

About Division of Cancer Prevention
The Division of Cancer Prevention (DCP) is the primary unit of the National Cancer Institute devoted to cancer prevention research. DCP provides funding and administrative support to clinical and laboratory researchers, multidisciplinary teams, and collaborative, research-based networks.

Contact
E: corpcomm@aragen.com